GPM6A is a glycoprotein in endothelial cells, and its biological function in the development of hepatocellular carcinoma (HCC) is unknown. Through Affymetrix gene expression microarray and bioinformatic analysis, very low GPM6A expression was found in HCC tissue. The present study aims to explore the function and regulatory mechanism of GPM6A in HCC development and progression. Levels of GPM6A expression in HCC specimens from different disorders and various hepatoma cell lines were determined, and its role on cell proliferation was evaluated in hepatoma cells stably overexpressing GPM6A. Modulation of a specific microRNA (miRNA) on its expression and function was evaluated with miRNA mimetic transfection. Herein, it is reported that much lower GPM6A levels were found in HCC tissues than pericancerous liver tissues and correlated to a poor prognosis. GPM6A overexpression inhibited cell proliferation, suppressed colony formation, migration and invasion in two hepatoma cell types. Available evidence does not support that genetic and epigenetic dysregulation contributes significantly to GPM6A inactivation in HCC. Additional findings demonstrated that miR-96-5p acted directly on the 3′-UTR of the GPM6A gene and significantly decreased its mRNA and protein levels. MiR-96-5p transfection promoted proliferation, migration and invasion of SMMC-7721 and MHCC-97H hepatoma cells; whereas the function of oncogenic microRNA-96 was significantly inhibited in GPM6A-overexpressed hepatoma cells. In conclusion, GPM6A expression in HCC is commonly suppressed regardless its base disease types, and its low expression in HCC tissues is most likely attributed to upregulated miR-96-5p. GPM6A may function as a valuable biomarker for HCC progression and prognosis.
Your institute does not have access to this article
Subscribe to Journal
Get full journal access for 1 year
We are sorry, but there is no personal subscription option available for your country.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Affymetrix analysis data is accessible at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99807.
Zhu H, Wu J, Shen X. Genome-wide association study: new genetic insights into HBV/HCV-related hepatocellular carcinoma genomes. Scand J Gastroenterol 52, 209-215 (2017).
Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 67, 862-873 (2017).
Diehl AM, Day C. Cause, Pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 377, 2063-2072 (2017).
Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease. Hepatology 71, 907-916 (2020).
Starley BQ, Calcagno CJ, Harrison S A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51, 1820-1832 (2010).
Ye J, Li TS, Xu G, Zhao YM, Zhang NP, Fan J et al. JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting lats2 kinase activity. Cancer Res 77, 5287-5300 (2017).
Zhou XT, Ding J, Li HY, Zuo JL, Ge SY, Jia HL et al. Hedgehog signalling mediates drug resistance through targeting TAP1 in hepatocellular carcinoma. J Cell Mol Med 24, 4298-4311 (2020).
Zhang L, Ding J, Li HY, Wang ZH, Wu J. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim Biophys Acta Rev Cancer 1874, 188441 (2020).
Park MH, Kwak S H, Kim KJ, Go MJ, Lee H J, Kim KS et al. Identification of a genetic locus on chromosome 4q34-35 for type 2 diabetes with overweight. Exp Mol Med 45, e7 (2013).
Formoso K, Billi S C, Frasch AC, Scorticati C. Tyrosine 251 at the C-terminus of neuronal glycoprotein M6a is critical for neurite outgrowth. J Neurosci Res 93, 215-229 (2015).
Charfi C, Edouard E, Rassart E. Identification of GPM6A and GPM6B as potential new human lymphoid leukemia-associated oncogenes. Cell Oncol (Dordr) 37, 179-191 (2014).
Fan YH, Ding J, Nguyen S, Liu X J, Xu G, Zhou HY et al. Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells. Oncogene 35, 116-124 (2016).
Wang ZH, Zheng KI, Wang XD, Qiao J, Li YY, Zhang L et al. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver. Hepatobiliary Pancreat Dis Int 20, 452-459 (2021).
Xu G, Ye J, Liu XJ, Zhang NP, Zhao YM, Fan J et al. Activation of pluripotent genes in hepatic progenitor cells in the transition of nonalcoholic steatohepatitis to pre-malignant lesions. Lab Invest 97, 1201-1217 (2017).
Chen X, Murad M, Cui YY, Yao LJ, Venugopal SK, Dawson K et al. miRNA regulation of liver growth after 50% partial hepatectomy and small size grafts in rats. Transplantation 91, 293-299 (2011).
Long J, Wang A, Bai Y, Lin J, Yang X, Wang D et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine 42, 363-374 (2019).
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133, 647-658 (2007).
Cancer Genome Atlas Research Network. Electronic address WBE, Cancer Genome Atlas Research N. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327-1341. e1323 (2017).
Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
Venugopal SK, Jiang J, Kim T H, Li Y, Wang SS, Torok NJ et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol 298, G101-106 (2010).
Shukla GC, Singh J, Barik S. MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol 3, 83-92 (2011).
Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64, 3753-3756 (2004).
Yang X, Liang L, Zhang XF, Jia H L, Qin Y, Zhu XC et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology 58, 158-170 (2013).
Michael M Z, SM O C, van Holst Pellekaan N G, Young G P, James R J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1, 882-891 (2003).
Feng X, Jiang J, Shi S, Xie H, Zhou L, Zheng S. Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway. Int J Oncol 49, 2600-2610 (2016).
Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107, 264-269 (2010).
Iwai N, Yasui K, Tomie A, Gen Y, Terasaki K, Kitaichi T et al. Oncogenic miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in hepatocellular carcinoma. Int J Oncol 53, 237-245 (2018).
Wang TH, Yeh CT, Ho J Y, Ng KF, Chen TC. OncomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting ephrinA5 in hepatocellular carcinoma. Mol Carcinog 55, 366-375 (2016).
Liu YM, Cao Y, Zhao PS, Wu L Y, Lu YM, Wang YL et al. CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway. Int J Biol Sci 18, 637-651 (2022).
Part of this work was presented in the American Association of Cancer Research (AACR) Annual Virtual Meeting II, Session title: Mechanisms of Tumor Suppressor Genes, AACR Abstract # 5970, June 24-26, 2020, Philadelphia, PA, USA; and published as an abstract in the Proceedings of AACR Annual Meeting 2020 (DOI: 10.1158/1538-7445). The authors are grateful to senior technologist Ke Qiao in the Technology Platform of Fudan University School of Basic Medical Sciences and Dr. Juan Ye in the Dept. of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Fudan University, Xiang-Nan Yu in the Dept. of Gastroenterology & Hepatology, Zhongshan Hospital of Fudan University, and Dr. Shengyang Ge in the Department of Abdominal Surgery, Huashan Hospital of Fudan University for their technical assistance.
This work is supported by the National Natural Science Foundation of China (NSFC #81572356, 81871997 and 82170624), the National Key R&D Program of China (#2016YFE0107400) to J.W.
The authors declare no competing interests.
Ethics approval and consent to participate
The use of human tissue was approved by the Ethic Committee of Fudan University School of Basic Medical Sciences, and followed guidelines of the Helsinki Declaration and the national, municipal, and university regulations.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Li, ZR., Xu, G., Zhu, LY. et al. GPM6A expression is suppressed in hepatocellular carcinoma through miRNA-96 production. Lab Invest (2022). https://doi.org/10.1038/s41374-022-00818-3